08:45 AM EST, 11/12/2024 (MT Newswires) -- Apogee Therapeutics ( APGE ) reported a Q3 net loss Tuesday of $49 million, wider than the loss of $20.8 million a year earlier.

Analysts polled by Capital IQ expected a loss of $43.9 million.

No revenue for the quarter ended Sept. 30 was reported.

As of Sept. 30, the company said it had $753.8 million in cash, cash equivalents and marketable securities, which it expects will enable it to fund its current operating expenses into Q1 2028.